Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Li G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the FinnishDiabetes Prevention Study. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Task Force Members, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. Pancreatic triacylglycerol distribution in type 2 diabetes. ![]() Hollingsworth KG, Al-Mrabeh A, Steven S, Taylor R. Prediabetes: a high-risk state for diabetes development. Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Ning F, Tuomilehto J, Pyörälä K, Onat A, Söderberg S, Qiao Q, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Komajda M, Tavazzi L, Francq BG, Böhm M, Borer JS, Ford I, et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/ hydralazine: consistency across subgroups in the African-AmericanHeart Failure Trial. Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? Ameta-analysis of large-scale clinical trials. The risk engine accurately predicts macro- and microvascular complications and would provide helpful information in risk classification and health economic simulations.Updated Updated Cardiovascular Prevention Guideline of the Brazilian Society Of Cardiology – 2019 Arq Bras Cardiol. By combining macro- and microvascular risks, the classification of low- and high-risk patients was improved by a net reclassification improvement of 5.7% (P = 0.02). C statistics in our Japanese patients were high for CHD, noncardiovascular mortality, and overt nephropathy (0.725, 0.696, and 0.767) but moderate for stroke and progression of retinopathy (0.636 and 0.614). In contrast, the UK Prospective Diabetes Study (UKPDS) risk engine overestimated CHD risk (O/P ratios: 0.30 for CHD and 0.72 for stroke). The observed-to-predicted (O/P) ratios for each event were between 0.93 and 1.08, and Hosmer-Lemeshow tests showed no significant deviations between observed and predicted events. Sex, age, HbA1c, years after diagnosis, BMI, systolic blood pressure, non-HDL cholesterol, albumin-to-creatinine ratio, atrial fibrillation, current smoker, and leisure-time physical activity were risk factors for macro- and microvascular complications and were incorporated into the risk engine. The predictive accuracy of the calculated 5-year risks was cross-validated. We fit a multistate Cox regression model to derive an algorithm for prediction. ![]() End points were coronary heart disease (CHD), stroke, noncardiovascular mortality, overt nephropathy defined by persistent proteinuria, and progression of retinopathy. We analyzed pooled data from two clinical trials on 1,748 Japanese type 2 diabetic patients without diabetes complications other than mild diabetic retinopathy with a median follow-up of 7.2 years. To develop and validate a risk engine that calculates the risks of macro- and microvascular complications in type 2 diabetes.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |